Form 4: LeMaitre Vascular Director Reports Dividend Accruals
Statement of Changes in Beneficial Ownership
Director Lawrence J. Jasinski reported the acquisition of dividend equivalent rights on existing equity awards.
Summary
- Director Lawrence J. Jasinski acquired a total of 4.0705 dividend equivalent rights on June 4, 2026.
- These rights accrued on previously granted restricted stock units and performance share units.
- Each dividend equivalent right represents the economic equivalent of one share of LeMaitre Vascular common stock.
- The acquisitions were made at a price of $0 per unit as they are tied to dividend distributions on existing holdings.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative event, as it represents the automatic accrual of dividends on existing equity rather than a discretionary purchase or sale.
Positives
- Reflects ongoing dividend distributions to equity holders, signaling consistent capital return policies.
Negatives
- None identified; this is a routine administrative filing regarding dividend accruals.
Risks
- Value of these rights is dependent on the underlying performance and vesting conditions of the original restricted stock and performance share unit awards.
Future Outlook
The filing does not provide forward-looking guidance regarding company operations or financial performance.
Industry Context
StockSavvy.ai notes that this filing is a standard regulatory disclosure for corporate insiders and does not indicate a change in strategic direction or market sentiment for the medical device sector.
Comparison to Industry Standards
- The reporting of dividend equivalent rights is a standard practice for directors and executives in the medical device industry to maintain alignment with shareholder interests.
Stakeholder Impact
- Minimal impact on shareholders as the transaction is a routine accrual of dividend rights.
Next Steps
- Vesting of the underlying restricted stock units and performance share units according to their respective grant schedules.
Key Dates
| Date | Description |
|---|---|
| 2023-12-08 | Grant date of initial restricted stock unit and performance share unit awards. |
| 2024-12-06 | Grant date of subsequent restricted stock unit and performance share unit awards. |
| 2025-12-10 | Grant date of additional restricted stock unit awards. |
| 2026-06-04 | Transaction date for the accrual of dividend equivalent rights. |
| 2026-06-05 | Filing date of the Form 4. |
Keywords
LeMaitre Vascular, LMAT, Form 4, Insider Trading, Dividend Equivalent Rights, Director Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.